

DAFTAR PUSTAKA

- Adzitey, F. 2015. Antibiotic classes and antibiotic susceptibility of bacterial isolates from selected poultry; a mini review. *World Vet J*, Vol. 5, No. 3: pp. 36-41.
- Anacona, J.R., Alina, B., & Maria E.L. 2013. Cefoperazone metal complexes: synthesis and characterization. *J Chil Chem Soc*, Vol. 58, No. 1: pp. 1521-1523.
- Anderson, P.O., James, E.K., & William, G.T. 2002. *Handbook of clinical drug data* (10th ed). New York: Mc. Graw Hill.
- Aymanns, C., Frieder, K., Sebastian, M., Bertram, H., & David, C. 2010. Review on pharmacokinetics and pharmacodynamics and the aging kidney. *Clin J Am Soc Nephrol*, Vol. 5: pp. 314-327.
- Baek, E.J., Lee, S., Kim, S., Choi, H.K., & Kim, H.O. 2009. A case of immune hemolytic anemia induced by ceftizoxime and cefobactam (sulbactam/cefoperazone). *Korean J Lab Med*, Vol. 29, No. 6: pp. 578-584.
- Bailey, R.R., Barbara, P., Elspeth, B., Vicky, B., & Reddy, J. 1981. Cefoperazone in the treatment of severe or complicated infections. *Drug*, Vol. 1: pp. 76-86.
- Bauer, L.A. 2008. *Applied clinical pharmacokinetics* (2nd ed). Washington: McGraw Hill.
- Bolton, W.K., Michael, S., Daniel, A.S., & Merle, A.S. 1981. Pharmacokinetics of cefoperazone in normal volunteers and subject with renal insufficiency. *Antimicrob Agents Chemother*, Vol. 19, No. 5: pp. 821-825.
- Boscia, J.A., Oksana, M.K., Richard, S., William, D.K., Matthew, E.L., & Donald, K. 1983. Cefoperazone pharmacokinetics in normal subjects and patients with cirrhosis. *Antimicrob Agents Chemother*, Vol. 23, No. 3: pp. 385-389.
- BPS. 2015. *Kebutuhan data ketenagakerjaan untuk pembangunan berkelanjutan*. Jakarta: Badan Pusat Statistik.
- Brunton, L.L., Bruce, C., & Bjorn, C.K. 2011. *Goodman & Gilman's the pharmacological basis of therapeutics* (12th ed). New York: McGraw-Hill Medical.
- Gaur, R., Azizi, M., Gan, J., Hansal, P., Harper, K., Mannan, R., Panchal, A., Patel, K., Patel, M., Patel, N., Rana, J., & Rogowska, A. 2009. *British*

pharmacopoeia. London: Medicine and Healthcare Product Regulatory Agency.

Cusack, B.J. 2004. Pharmacokinetics in older person. *Am J Ger Pharmacotherapy*, Vol. 2, No. 4: pp. 274-302.

Debnath, S., Hima, B.P., Niranjan, B.M., Isaquiddhin, K.M.D., & Vanitha, G. 2014. Pharmacokinetics in geriatric patients. *Scandanavian J Pharmaceu Sci Res*, Vol. 1, No. 1: pp. 14-19.

Grizzi, F., Giuseppe, D.C., Luigi, L., Paul, H., Paolo, M., Diane, D.N., Saba, R., Jose, A.F., Everardo, C., Giorgio, A., & Maurizio, C.I. 2013. Mast cells and the liver aging process. *Bio Med Central*, Vol. 10, No. 9.

Horiuchi, A. Hirofumi, H., Takashi, K., Teruo, K., Tohru, M., Kojiro, Y., Hiroya, K., & Kiyoyasu, N. 1989. Efficacy of sulbactam/cefoperazone for the treatment of infections in patiens with hematologic disease. *Diag Microbio Inf Dis*, Vol. 12, No. 4: pp. 215-219.

Kaplowitz, L.G., & Sarrubi, F.A. 1983. Treatment of lower respiratory tract infections with cefoperazone. *Clin Ther*, Vol. 5, No. 3: pp.243-250.

Katzung, B.G. 2012. *Basic & clinical pharmacology* (12th ed). New York: McGraw Hill.

Kaye, A.D., Amir, B., & Jaret, T.S. 2010. Pain management in the elderly population: a review. *Ochsner J*, Vol. 10, No. 3: pp.179-187.

Kementrian Kesehatan RI. 2014. *Farmakope Indonesia* (Edisi V). Jakarta: Kementrian Kesehatan RI.

Kementrian Kesehatan RI. 2012. *Profil Kesehatan Indonesia*. Jakarta: Kementrian Kesehatan RI.

Klastersky, J. 1988. Cefoperazone in the treatment of infections in cancer patients. *Am J Med*, Vol. 85, No. 1: pp. 9-16.

Kratzsch, D., & Regina, T. 2014. Dermatologic therapy in geriatric patients. *J D D G*, Vol.12, No. 8: pp. 653-665.

Kuntaman, K., Sanarto, S., Hendro, W., Ni, M.M., Endang, S.L., Helmia, F., Rebriana, H., Stefani, C.F., Noorhamdi, A.S., Dewi, S., Priyo, B.P., & Deby, K. 2011. The sensitivty pattern of extended spectrum beta lactamase-producing bacteria against six antibiotics that rountinely used in clinical setting. *J Indon Med Assoc*, Vol. 62, No. 12: pp. 482-486.

- Leeuwen, A.M.V., & Mickey L.B. 2015. *Davis's comprehensive handbook of laboratory and diagnostic test with nursing implication*. Philadelphia: FA Davis Company.
- Mangoni, A.A., & Jackson, H.D. 2003. Age-related changes in pharmacokinetics and pharmacodynamics: basic principle and practical application. *Br J Clin Pharmacol*, Vol. 57, No.1: pp. 6-14.
- Martono, H. 2009. *Buku ajar geriatri (ilmu kesehatan usia lanjut)*. Jakarta: Balai penerbit Fakultas Kedokteran Universitas Indonesia.
- Masoud, M.S., Alaa, E.A., & Nessma, M.N. 2014. Chemistry, classification, pharmacokinetics, clinical uses and analysis of beta lactam antibiotics: a Review. *J Chem Pharm Res*, Vol. 6, No. 11; pp. 28-58.
- Meyers, B.R., Meryl, H.M., Roberts, G.D., Elina, S.C., Melody, T.S., & Shalom, Z.H. 1987. Pharmacokinetics of cefoperazone in ambulatory elderly volunteers compared with young adults. *Antimicrob Agents Chemother*, Vol. 31, No. 6: pp. 925-929.
- Mclean, A.J., & David, G.L.C. 2004. Aging biology and geriatric clinical pharmacology. *Pharmacol Rev*, Vol. 56, No. 2: pp. 163-184.
- Midlov, P. 2013. Pharmacokinetics and pharmacodynamics in the elderly. *OA Eld Med*, Vol. 1, No. 1: pp. 1-5.
- Mitchell, S.J., Alice, E.K., & Sarah, N.H. 2011. Age related changes in the hepatic pharmacology and toxicology of paracetamol. *Current Gerontology Ger Res*, Vol. 2011: pp. 1-14.
- Naveed, S., Amna, A.B., Anum, J., Faiza, N., Madiha, Q., Firdous, A., & Mariam, K. 2014. Increased use of cephalosporin as first line agent instead of penicillin. *World J Pharm Sci*, Vol. 2, No. 4: pp. 270-275.
- Notoatmojo, S. 2002. *Metodologi penelitian kesehatan*. Jakarta: Penerbit PT. Rineka Cipta.
- Pantakar, M., Sangita, S., Anita, C., Usha, N., & Loraine, S. 2012. Comparative in-vitro of cefoperazone-tazobactam and cefoperazone-sulbactam combinations against ESBL pathogens in respiratory and urinary infections. *J A P I*, Vol. 60: pp. 22-24.
- Presiden RI. 2004. Peraturan Pemerintah: *Pelaksanaan upaya peningkatan kesejahteraan sosial lanjut*. Jakarta: Presiden RI.
- Pugh, R.N.H., Murray, L., Dawson, J.L., Pietroni, M.C., & Roger. M. 1973. Transection of the oesophagus for bleeding oesophageal varices. *Brith J Surg*, Vol. 60, No. 8: pp. 646-649.

- Rehman, H., Regina, Q.U., & Sakatschewan. 2013. A typical manifestations of medical conditions in the elderly. *CGS J CME*, Vol. 3, No. 1: pp. 17-24.
- Schwartz, J.I., Luis, E.J., Kenneth, A.B., Mary, E.M., & Donald, P.R. 1988. Multiple-dose pharmacokinetics of intravenously administered cefoperazone and sulbactam when given in combination to infected, seriously ill, elderly patients. *Antimicrob Agents Chemother*, Vol. 3, No. 5: pp. 730-735.
- Shargel, L, Andrew B.C., & Sussanna W.U. 2005. *Applied Biopharmaceutics and Pharmacokinetics fifth edition*. Boston: Appleton Century Croft.
- Singh, M., & Kochhar, P. 2010. Optimizing pharmacokinetic/pharmacodynamics principle & role of sefoperazon – sulbactam. *J Med Res Div*, Vol. 1: pp. 1074-1080.
- Soni, H.H., Patel, R.J., Sadariya, K.A., Devada, S.S., Bhavsar, S.K., & Thaker, A.M. 2012. Single dose pharmacokinetics of sefoperazon following intravenous and intramuscular administration in sheep. *Israel J Veterinary Med*, Vol. 67, No. 4: pp. 220-224.
- Stockley, I.H. 2008. *Stockley's drug interaction*. (8th ed). London: Pharmaceutical Press.
- Stringer, J.L. 2006. *Basic concepts in pharmacology*. New York: McGraw Hill.
- Sweetman, S.C. 2009. *Martindale the complete drug reference* (36th ed). London: Pharmaceutical Press.
- Tajiri, K., & Yukihiro, S. 2013. Liver physiology and liver disease in the elderly. *W J G*, Vol. 19, No. 46: pp. 8459-8468.
- Tatro, D.S. 2003. *A to Z drug facts*. San Fransisco: Facts and Comparisons.
- Undang-Undang Republik Indonesia No.13 Tahun 1998 tentang kesejahteraan manusia, Bab I, Pasal 1: ayat 2,3,4.
- Ullah, H.A., Iqbal, J., Khan, K., Hanif, M., & Jamil, S. 2013. In-vitro comparative study of cefoperazone, ceftazidime, ceftizoxime, cefotaxime, ceftriaxone and cefixime against *Pseudomonas aeruginosa*. *I R J P*, Vol. 4, No. 1: pp. 135-137.
- Urbanek, K., Kolar, M., Loveckova, Y., Strojil, J., & Santava, L. 2007. Influence of third-generation cephalosporin utilization on the occurrence of esbl-positive *Klebsiella pneumonia* strains. *J Clin Pharm Therapeu*, Vol. 32: pp. 403-408.
- VanMeter, K.C., & Robert, J.H. 2014. *Gauld's pathophysiology for the health professions*. Canada: Elsevier

Weinstein, J.R., & Sharon, A. 2010. The aging kidney: physiological changes. *Adv Chronic Kidney Dis*, Vol. 17, No. 4: pp. 302-307.

World Health Organization. 2010. *Global health and aging*. Washington, DC: World Health Organization.

Yine, L., & Young, F. 2009. Evidence-based analysis of thrombocytopenia caused by cefoperazone/sulbactam. *Chinese Pharmaceu J*, Vol. 24: pp. 24-30.

